Actress Pamela Anderson has opened up about her hepatitis C diagnosis that once made her fear she had only a few years to live, highlighting how dramatically treatment for the viral infection has changed.Speaking at the 2026 amfAR Gala Venezia during the Venice Film Festival, Anderson recalled being diagnosed with hepatitis C in 2002. She said doctors had told her she had around 10 years to live, describing the diagnosis as a “death sentence”.Anderson has previously said she contracted hepatitis C after sharing a tattoo needle with her then-husband Tommy Lee. At the time, the diagnosis carried significant uncertainty because effective curative treatments were not yet available. But more than a decade later, Anderson announced that she had been cured of hepatitis C following antiviral treatment.What Is Hepatitis C?Hepatitis C is a viral infection that primarily affects the liver. It is transmitted through contact with infected blood and can become a chronic infection. While some people clear the virus on their own, most people with hepatitis C who do not clear it develop chronic infection. Over time, chronic hepatitis C can cause liver cirrhosis, liver failure and liver cancer.According to the World Health Organization (WHO), an estimated 47 million people were living with chronic hepatitis C globally, with about 0.9 million new infections occurring each year. In 2024, approximately 239,000 people died from hepatitis C, mainly due to cirrhosis and liver cancer.Also read: The Silent Killer: Why More Indians Need To Pay Attention To Liver CancerHow Did Hepatitis C Become Curable?The major breakthrough came with the development of direct-acting antivirals (DAAs). Before these medicines became available, hepatitis C treatment relied heavily on interferon-based therapies, which could involve prolonged treatment and significant side effects and did not cure everyone.The first interferon-free DAA treatments were approved in 2013 and 2014, marking a major turning point in hepatitis C treatment. WHO says these medicines can cure the infection in more than 95% of people, generally within a short course of treatment.Unlike older treatments, DAAs directly target the hepatitis C virus and prevent it from multiplying. Treatment is now usually oral, much better tolerated and considerably shorter than earlier regimens.WHO recommends pan-genotypic DAAs for people with chronic hepatitis C, with treatment generally lasting around 12 to 24 weeks depending on the person's condition.Also read: RFK Jr. Accepts Pennsylvania Child’s Measles Death After Questioning It: Here's WhyAccess Remains A Challenge The transformation in treatment does not mean hepatitis C has disappeared. There is currently no vaccine against hepatitis C, and millions of people remain undiagnosed. WHO estimates that by the end of 2024, only around 36% of people who had ever been infected knew their diagnosis, while only about 20% of those diagnosed with chronic infection had received DAA treatment. This makes early testing and access to treatment critical.Anderson's experience also reflects how quickly medicine can change the outlook of a disease. “I’m not a victim, I’m a victor,” Anderson said while accepting the amfAR Award of Courage in Venice.